A Study of P38 Inhibitor (4) Monotherapy in Patients With Active Rheumatoid Arthritis
A Randomized, Double-blind Study to Compare the Effect of RO4402257 Monotherapy and Methotrexate Monotherapy on Disease Response in Patients With Active Rheumatoid Arthritis.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada, T5H 3V9
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 2Y9
-
-
Ontario
-
Ottawa, Ontario, Canada, K2G 6E2
-
Toronto, Ontario, Canada, M5T 2S8
-
-
-
-
-
Rijeka, Croatia, 51000
-
Split, Croatia, 21000
-
-
-
-
-
Ceské Budejovice, Czech Republic, 370 01
-
Praha, Czech Republic, 128 50
-
Terezin, Czech Republic, 411 55
-
Zlin, Czech Republic, 760 01
-
-
-
-
-
Brest, France, 29609
-
Corbeil-essonnes, France, 91106
-
Montpellier, France, 34295
-
Paris, France, 75679
-
Rouen, France, 76031
-
-
-
-
-
Brescia, Italy, 25123
-
Genova, Italy, 16132
-
Pavia, Italy, 27100
-
Roma, Italy, 00161
-
-
-
-
-
Guadalajara, Mexico, 44620
-
Guadalajara, Mexico, 44340
-
Miexico City, Mexico, 06700
-
-
-
-
-
Brasov, Romania, 500366
-
Bucharest, Romania, 020125
-
-
-
-
-
Belgrade, Serbia, 11000
-
-
-
-
-
Bloemfontein, South Africa, 9301
-
Johannesburg, South Africa, 1619
-
Pretoria, South Africa, 0002
-
-
-
-
-
Barcelona, Spain, 08035
-
Granada, Spain, 18014
-
Jerez de La Frontera, Spain, 11407
-
La Coruna, Spain, 15006
-
Madrid, Spain, 28040
-
Oviedo, Spain, 33006
-
Palma de Mallorca, Spain, 07007
-
Sevilla, Spain, 41013
-
-
-
-
-
Kaohsiung, Taiwan, 00833
-
Taoyuan, Taiwan, 333
-
Tapei, Taiwan, 114
-
-
-
-
Alabama
-
Aniston, Alabama, United States, 36207
-
-
Arizona
-
Scottsdale, Arizona, United States, 85251
-
Tucson, Arizona, United States, 85704
-
Tucson, Arizona, United States, 85712
-
-
California
-
Escondido, California, United States, 92025
-
Loma Linda, California, United States, 92357
-
-
Connecticut
-
Stamford, Connecticut, United States, 06905
-
-
Illinois
-
Morton Grove, Illinois, United States, 60053
-
-
Indiana
-
South Bend, Indiana, United States, 46601
-
-
Kansas
-
Wichita, Kansas, United States, 67207
-
-
Kentucky
-
Louisville, Kentucky, United States, 40292
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70115
-
-
North Carolina
-
Belmont, North Carolina, United States, 28012
-
-
Oregon
-
Bend, Oregon, United States, 97701
-
-
Pennsylvania
-
Danville, Pennsylvania, United States, 17822
-
Lancaster, Pennsylvania, United States, 17604
-
-
South Carolina
-
Charleston, South Carolina, United States, 29407
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37909
-
Memphis, Tennessee, United States, 38104
-
Nashville, Tennessee, United States, 37203
-
-
Texas
-
Amarillo, Texas, United States, 79106
-
Dallas, Texas, United States, 75231
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- adult patients >18 years of age, with active RA;
- receiving treatment for RA on an outpatient basis;
- females of child-bearing potential, or nonsterilized males with partners of child-bearing potential, must use reliable contraception during, and for 4 weeks after, the study.
Exclusion Criteria:
- major surgery within 8 weeks prior to screening;
- rheumatic autoimmune disease or inflammatory joint disease other than RA;
- treatment with methotrexate within 8 weeks of baseline;
- concurrent use of DMARDs, including anti-TNF or other biologic therapy for RA.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1
|
50mg po qd
150mg po qd
300mg po qd
|
|
Experimental: 2
|
50mg po qd
150mg po qd
300mg po qd
|
|
Experimental: 3
|
50mg po qd
150mg po qd
300mg po qd
|
|
Placebo Comparator: 4
|
po qd
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of patients with ACR 20 response
Time Frame: Week 12
|
Week 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of patients with ACR 50/70 response.
Time Frame: Week 12
|
Week 12
|
|
Change in ACR core set, DAS 28, FACIT-F fatigue assessment, AEs, laboratory parameters.
Time Frame: Throughout study
|
Throughout study
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PA18604
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.